



Request for Proposal (RFP) for Independent Medical Education (IME)

Adjuvant Therapy in Endometrial Cancer

Therapeutic Area	Endometrial Cancer
Sub-area of Interest	Multi-Disciplinary Team
Intended Learners	Medical Oncologists, Gynecologic Oncologists, Pathologists, Oncology Nurses
Budget	\$300,000
Geographic Coverage	United States
References	Supportive citations are provided beginning on page 4.
Submission Deadline	Thursday, April 4, 2024, 11:59 pm ET
Submission	www.msdgrant.com
Submission code	EC2024MDT

Background

Our values represent the core of our character and guide every decision and action we take, leading with patients first. We support quality IME for healthcare professionals (HCPs) designed to improve patient health outcomes, across a variety of scientific areas. Global Professional Relations and Independent Medical Education (gPRIME) aims to be the world class industry leader collaborating with professional organizations to support innovative IME, advancing knowledge, competence, and performance of HCPs to help improve patient care and health outcomes. Education which allows for reinforcement of the learning objectives is key to long-term performance optimization, as is the incorporation of tools and ongoing reminders for HCPs that help them apply their knowledge. The best way to improve patient care is through the application of relevant and appropriate medical education.

In the United States, the National Cancer Institute estimates 66,200 new cases of endometrial cancer, and its incidence is projected to rise in the upcoming years. A person's risk of endometrial cancer recurrence depends on a variety of factors specific to them, as an individual, as well as the tissue histology. The use of adjuvant treatment may decrease the risk of recurrence amongst individuals predisposed to a high risk of disease recurrence. While algorithm nuances surrounding adjuvant interventions are in a constant state of change due to recent advancements of science, the development of new surgical and radiotherapy techniques, molecular profiling, and the approval of new medications, recommendations to provide adjuvant options remain unchanged. Without adjuvant treatment, patients with tp53 abnormalities, uterine serous carcinoma or clear cell carcinoma are at an even higher risk for recurrence of their endometrial cancer, compared to patients without these disease distinctions or compared to women who have received adjuvant treatment for their tumor.

There are a host of highly skilled medical professionals including, for example, medical oncologists, gynecologic oncologists, radiation oncologists, pathologists, supporting nursing and pharmacy subspecialties contributing to the management of a patient with newly diagnosed endometrial cancer. Individual teams may have variations in their approach to patient care depending on available resources. Coordination of these roles is essential to staying current with the latest scientific advancements, minimizing disease progression, and minimizing complications from surgical and medical interventions. Interprofessional education creates a collaborative, team-based approach to closing knowledge and performance gaps, and is intended to ultimately improve clinical practice. Working together, a collaboration amongst HCPs helps deliver optimal interventions for patients and build mutually respectful workplaces.

Identified Educational Gap(s)

The gPRIME team at Our Company identified several practice gaps surrounding competency deficiencies of HCPs working within an oncology multidisciplinary team through outcomes identified in independent educational needs assessments. These gaps can be effectively addressed through IME for HCPs working to advance patient health outcomes for patients with endometrial cancer. Our Company would like to support the following educational gaps within the multidisciplinary team:

- *The need for physicians who treat patients with endometrial cancer to confidently apply guideline concordant therapeutic interventions, particularly in the adjuvant setting*
- *The need for an oncology multidisciplinary team to confidently utilize each other's expertise to support decision making, particularly with regard to adjuvant treatment*
- *The need for each member of the oncology multidisciplinary team to correctly identify biomarker tests to determine the presence of mutations in genes implicated in classifying a tumor as high-risk*
- *The need for members of the oncology multidisciplinary team to appropriately apply identified risk factors across stages of disease (i.e., biomarkers, histology, etc.) to treatment decision making*

Our Company is looking to support education to narrow or close these gaps; however, depending on the needs identified by the providers, the education may not be able to address all these educational gaps in a single proposal.

Eligibility Criteria

- **U.S. based** professional associations and medical societies, healthcare institutions, medical education companies, and other organizations committed to improving the quality of healthcare delivered to individuals, through the education of HCPs, may apply for this grant.
- The applicant must be an accredited provider in good standing by the Accreditation Council for Continuing Medical Education (ACCME), American Nursing Credentialing Center (ANCC), American Council for Pharmacy Education (ACPE), or have Joint Accreditation for interprofessional continuing education.
- The selected grant recipient will need to attest to the terms, conditions, and purposes of the independent educational grant as described in Our Company's Letter of Agreement, and comply with current ethical codes and regulations.

Prioritization of Grant Applications

Our Company will evaluate all complete grant applications, and will give priority to those most likely to independently validate the aforementioned educational and performance gaps specific to the needs of specific cohorts of learners. Proposals should be built around the educational or performance need (including an identification of current knowledge or practice of targeted learners contrasted with ideal knowledge and practice), supported with aligned learning objectives, constructed with appropriate instructional design and adult learning theory, and evaluated using Moore's scale of educational effectiveness. Our Company encourages application submission to additional commercial supporters with similar scientific interests.

Our Company appreciates the complexity of education required for HCPs to help improve patient health outcomes. In our experience, collaboration between medical

education providers may yield better educational outcomes by enabling multi-modal education and developing tools and resources for a broader group of learners.

Terms and Conditions

The selected grant recipient shall be bound by the terms and conditions found in the Our Company's Letter of Agreement.

References

- Data on file. Independent Medical Education, measures of educational effectiveness. Merck & Co., Inc. Improving Provider Awareness About Healthcare Equity: Improving All Patients' Access to Care in Endometrial Cancer. Pretest. CCO. Available at: <https://clinicaloptions.com/activity/ecase/87828F50-3C2C-42BB-A4D4-BBAA7E107088/1>. Accessed: January 24, 2024.
- Joint Accreditation. Benefits of IPCE. Available at: [Interprofessional Continuing Education Benefits | Joint Accreditation](#). Accessed: January 24, 2024.
- Knisely A, Huang Y, Li Y, Prabhu VS, Wright JD. Adjuvant and first line chemotherapy use for endometrial cancer. *Gynecologic Oncol Rep*. 2022;41.
- Li Y, Perera C, Chen L, et al. A data-driven disease burden model based on molecular classification in endometrial cancer patients in five European countries and the United States. Presented at: European Society of Gynaecological Oncology. September 28, 2023. Istanbul, Turkey.
- Moore DE, Green JS, Gallis HA. Achieving desired results and improved outcomes: integrating planning and assessment throughout learning activities. *J Contin Educ Health Prof*. 2009;29(1):1-15.
- Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Uterine Cancer. National Cancer Institute. Available at: <https://seer.cancer.gov/statfacts/html/corp.html>. Accessed: January 24, 2024.